Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Business Model:
Revenue: $10M
Employees: 201-500
Address: 55 Cambridge Pkwy Ste 800E
City: Cambridge
State: MA
Zip: 02142
Country: US
Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. They accelerate Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning with seemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology. Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies. They attract, develop, and retain the top scientific, entrepreneurial, and managerial talent in the world.
Contact Phone:
+16178681888
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2007 | LS9 | Series A | 5M |
12/2013 | Axcella | Series B | - |
5/2014 | Seres Therapeutics | Series B | 10M |
11/2013 | Seres Therapeutics | Series A | 10.5M |
10/2005 | Integrated Development Enterprise | Venture Round | 1.5M |
3/2004 | Zalicus | Series D | 29.5M |
11/2006 | Tetraphase Pharmaceuticals | Series A | 10M |
3/2006 | Tira Wireless | Series C | 13M |
8/2008 | Tetraphase Pharmaceuticals | Series A | 0 |
8/2011 | T2 Biosystems | Series D | 0 |
1/2008 | Carbon Design Systems | Series E | 6M |
10/2021 | CIBO Technologies | Series C | 0 |
5/2009 | Carbon Design Systems | Series E | 7.5M |
7/2020 | Omega Therapeutics | Series B | 85M |
9/2009 | Tetraphase Pharmaceuticals | Series B | 0 |
1/2002 | Renovis | Series B | 0 |
10/2007 | Interactive Supercomputing | Series B | 11M |
9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
1/2015 | Tarveda Therapeutics | Series B | 21M |
1/2016 | Codiak Biosciences | Series B | 61M |
1/2006 | Calpurnia Corporation | Series B | 8M |
5/2011 | YourBio Health | Series A | 4.5M |
3/2010 | Sesen Bio, Inc. | Series A | 35M |
11/2017 | Repertoire Immune Medicines | Series A | 25M |
10/2007 | LS9 | Series B | 15M |
6/2005 | Brainshark | Series C | 0 |
4/2010 | Joule Unlimited, Inc. | Series B | 30M |
9/2004 | Ellacoya Networks | Venture Round | 7M |
11/2012 | Tangent Medical Technologies | Series B | 8.6M |
7/2002 | Continuum Photonics | Series B | 14M |
9/2006 | Intio | Series B | 2M |
7/2008 | Accuri Cytometers | Series C | 13M |
12/2005 | Resolvyx Pharmaceuticals | Series A | 17M |
1/2012 | Tarveda Therapeutics | Series A | 2.8M |
7/2004 | BlackDuck | Series A | 5M |
1/2002 | CombinatoRx | Series B | 40M |
1/2001 | AnVil Informatics, Inc | Series A | - |
6/2010 | Acceleron Pharma | Venture Round | 10.3M |
1/1999 | Integrated Development Enterprise | Seed Round | - |
7/2005 | Ellacoya Networks | Series D | 13.5M |
2/2007 | BlackDuck | Series C | 12M |
5/2005 | Codon Devices | Series A | 13M |
9/2007 | Kovio | Series D | 19.5M |
6/2003 | Nanostream Inc. | Series C | 22M |
5/2008 | Mascoma | Series C | 61M |
6/2011 | Kovio | Venture Round | 0 |
8/2007 | Adnexus | Series C | 15.5M |
3/2021 | Omega Therapeutics | Series C | 126M |
2/2012 | Helicos BioSciences | Series A | 27M |
12/2013 | Tarveda Therapeutics | Series B | 21M |
10/2006 | Morphotek | Series D | 0 |
7/2004 | ZoomInfo | Series A | 7M |
11/2012 | Quanterix | Series C | 0 |
11/2011 | Agios | Series C | 78M |
9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
1/2021 | Tessera Therapeutics | Series B | 0 |
8/2022 | Senda Biosciences | Series C | 123M |
1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
3/2013 | T2 Biosystems | Series E | 40M |
6/2006 | Adnexus | Series B | 27M |
8/2010 | Visterra | Debt Financing | 6M |
10/2014 | Visterra | Series B | 30M |
8/2005 | Pervasis Therapeutics | Series B | 12.4M |
9/2012 | WikiCell Designs | Series A | 10M |
10/2006 | SiCortex | Series B | 21M |
3/2013 | Receptos | Series B | 30M |
8/2006 | Acceleron Pharma | Series B | 30M |
10/2014 | Selecta Biosciences | Private Equity Round | 20M |
3/2003 | Adnexus | Series A | 13M |
8/2009 | Pervasis Therapeutics | Series C | 17.4M |
12/2005 | Hypnion | Series B | 0 |
6/2010 | BIND Therapeutics | Series C | 12.4M |
2/2009 | Selecta Biosciences | Series B | 15.1M |
10/2014 | Syros Pharmaceuticals | Series B | 53M |
3/2013 | Janssen Global Services | Venture Round | 13.5M |
4/2011 | Janssen Global Services | Series B | 18.4M |
8/2014 | YourBio Health | Series B | 16M |
11/2012 | Visterra | Series A | 26.1M |
6/2016 | Visterra | Series C | 23.1M |
4/2004 | Continuum Photonics | Series C | 17.5M |
9/2004 | SiCortex | Series A | 21M |
4/2008 | Concert Pharmaceuticals | Series C | 0 |
3/2010 | TransMedics | Series E | 0 |
6/2009 | Polatis | Venture Round | 8M |
2/2004 | Morphotek | Series C | 26M |
10/2007 | Acceleron Pharma | Series C | 31M |
1/2005 | Revivio | Series C | 25M |
10/2003 | AVEO Oncology | Series B | 42.7M |
12/2010 | LS9 | Series D | 30M |
12/2006 | Codon Devices | Series B | 20M |
8/2015 | Editas Medicine | Series B | 0 |
2/2017 | Tarveda Therapeutics | Series D | 30M |
7/2009 | Kovio | Series E | 20M |
6/2010 | Tetraphase Pharmaceuticals | Series C | 0 |
1/2019 | Sana Biotechnology | Seed Round | - |
2/2012 | Polatis | Venture Round | 0 |
8/2016 | Denali Therapeutics | Series B | 130M |
10/2010 | Accuri Cytometers | Series E | 6M |
8/2009 | Accuri Cytometers | Series D | 4M |
9/2014 | BlackDuck | Series F | 0 |
6/2020 | Sana Biotechnology | Series A | 700M |
4/2022 | Tessera Therapeutics | Series C | 0 |
6/2003 | Trusted Network Technologies | Series A | 6M |
1/2012 | Joule Unlimited, Inc. | Series C | 70M |
10/2019 | Cygnal Therapeutics | Venture Round | 65M |
8/2004 | Affinnova | Series C | 4.5M |
12/2022 | Montai Health | Series A | 50M |
2/2021 | Cellarity | Series B | 0 |
12/2004 | Pervasis Therapeutics | Series A | 2M |
8/2005 | Extraprise | Venture Round | 0 |
12/2017 | Janssen Global Services | Series B | 25M |
1/2008 | Pervasis Therapeutics | Venture Round | 9.8M |
8/2017 | Omega Therapeutics | Series A | 28.4M |
5/2015 | Axcella | Series C | 39M |
1/2020 | Invaio Sciences | Venture Round | - |
3/2022 | Vesalius Therapeutics | Venture Round | 75M |
7/2007 | Ze-gen | Series A | 5.5M |
3/2013 | Avedro | Series D | 0 |
2/2007 | Everyday Solutions | Series A | 6.8M |
5/2022 | ProFound Therapeutics | Private Equity Round | 75M |
1/2009 | Celexion | Venture Round | - |
11/2012 | TransMedics | Venture Round | 36M |
7/2016 | Indigo | Series C | 100M |
9/2018 | Indigo | Series E | 250M |
9/2017 | Indigo | Series D | 203M |
5/2009 | Visterra | Seed Round | 3.3M |
11/2013 | Moderna Therapeutics | Venture Round | 110M |
1/2020 | Ohana Biosciences | Venture Round | - |
11/2013 | Editas Medicine | Series A | 43M |
3/2004 | Pervasis Therapeutics | Seed Round | 500k |
11/2021 | Alltrna | Venture Round | 50M |
1/2020 | Ring Therapeutics | Venture Round | 50M |
10/2015 | Janssen Global Services | Venture Round | 32M |
3/2003 | Hypnion | Series B | 47.5M |
11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
8/2009 | Advanced Electron Beams | Series C | 0 |
9/2005 | Carbon Design Systems | Series C | 5.3M |
2/2005 | Seahorse Bioscience | Series C | 11.5M |
6/2003 | Ellacoya Networks | Venture Round | 14M |
3/2009 | Seahorse Bioscience | Series D | 6M |
11/2013 | EcoSense Lighting | Venture Round | 15M |
1/2004 | Genomics Collaborative | Venture Round | - |
2/2016 | Indigo | Series B | 48.5M |
2/2009 | BlackDuck | Series D | 5M |
7/2019 | Valo Health | Series A | 100M |
10/2002 | Tira Wireless | Series A | 3M |
7/2007 | Tira Wireless | Series D | 5M |
5/2015 | Denali Therapeutics | Series A | 217M |
1/2003 | VIEO | Series B | 15M |
3/2020 | Sigilon | Series B | 80.3M |
1/2004 | Carbon Design Systems | Series B | 10M |
12/2014 | Seres Therapeutics | Series C | 48M |
1/2007 | Ensemble Therapeutics | Venture Round | - |
6/2018 | Kaleido | Series C | 101M |
6/2006 | Zingku | Venture Round | 1M |
5/2015 | Joule Unlimited, Inc. | Private Equity Round | 40M |
5/2012 | Sesen Bio, Inc. | Series A | 20M |
10/2007 | BDNA | Series D | 0 |
6/2012 | YourBio Health | Series A | 10M |
1/2006 | Interactive Supercomputing | Series A | 4.5M |
11/2015 | Evelo Biosciences | Series A | 35M |
4/2009 | Avedro | Series B | 10M |
3/2017 | Oasys Water | Series B | 4M |
10/2005 | Affinity Express | Venture Round | 3M |
2/2007 | BIND Therapeutics | Series A | 2.5M |
2/2002 | BG Medicine | Venture Round | 11M |
9/2006 | Carbon Design Systems | Series D | 5M |
11/2014 | Indigo | Series A | 7.5M |
11/2015 | Codiak Biosciences | Series A | 31M |
6/2011 | MedidaMetrics | Venture Round | 8.5M |
9/2003 | Selventa | Series A | 0 |
1/2003 | Blue Agave Software | Series A | 7M |
10/2009 | LS9 | Series C | 25M |
1/2006 | T2 Biosystems | Series A | 5.5M |
5/2010 | T2 Biosystems | Series C | 0 |
1/2018 | Inzen Therapeutics | Venture Round | - |
12/2013 | Visterra | Series A | 8.1M |
10/2022 | Cellarity | Series C | 121M |
9/2021 | YourBio Health | Venture Round | 21M |
3/2006 | Helicos BioSciences | Series B | 40M |
7/2016 | TransMedics | Private Equity Round | 0 |
11/2016 | YourBio Health | Series C | 10M |
12/2019 | Cellarity | Funding Round | 50M |
8/2002 | Flamenco Networks | Series B | 7.4M |
10/2022 | Inari | Series E | 0 |
8/2005 | Intio | Series A | 829k |
9/2018 | KSQ Therapeutics | Series C | 80M |
12/2002 | Integrated Development Enterprise | Venture Round | 13.3M |
3/2017 | CIBO Technologies | Venture Round | 30.3M |
4/2007 | TransMedics | Series D | 0 |
9/2017 | Kaleido BioSciences | Series B | 65M |
11/2006 | Mascoma | Series B | 30M |
7/2008 | Agios | Series A | 33M |
10/2017 | KSQ Therapeutics | Series B | 76M |
5/2021 | Inari | Series D | 0 |
11/2007 | BIND Therapeutics | Series B | 16M |
9/2020 | Generate Biomedicines | Venture Round | 50M |
5/2021 | Invaio Sciences | Series C | 88.9M |
3/2002 | Affinnova | Series A | 4M |
3/2004 | CombinatoRx | Series C | 30M |
2/2009 | Oasys Water | Series A | 10M |
11/2009 | Receptos | Series A | 25M |
2/2015 | EcoSense Lighting | Series C | 25M |
8/2021 | Laronde | Series B | 440M |
7/2008 | BG Medicine | Series D | 40M |
3/2015 | Red Rock Biofuels | Venture Round | - |
6/2005 | BlackDuck | Series B | 12M |
11/2018 | Axcella | Series E | 0 |
7/2021 | Ring Therapeutics | Series B | 117M |
1/2021 | Valo Health | Series B | 190M |
5/2005 | Netuitive | Series C | 5M |
7/2006 | Mascoma | Series A | 4M |
8/2020 | Indigo | Series F | 360M |
4/2021 | Repertoire Immune Medicines | Series B | 0 |
1/2017 | Incredible Foods | Venture Round | - |
8/2002 | NuVox | Private Equity Round | 78.5M |
9/2003 | IntelliVid | Series A | 5.5M |
8/2019 | Inari | Series C | 89M |
7/2003 | Affinnova | Series B | 6M |
6/2009 | Janssen Global Services | Series A | 15M |
5/2008 | Intio | Convertible Note | 1M |
3/2018 | Foghorn Therapeutics | Venture Round | 50M |
7/2022 | Apriori Bio | Series A | 0 |
10/2013 | Axcella | Series A | 10.8M |
5/2021 | Laronde | Series A | 50M |
12/2015 | Rubius Therapeutics | Series A | 25M |
6/2012 | Tangent Medical Technologies | Venture Round | 7.9M |
12/2003 | Blue Agave Software | Series B | 6M |
6/2010 | Everyday Solutions | Venture Round | 2.8M |
1/2006 | Epitome Biosystems | Venture Round | - |
5/2016 | TransMedics | Series F | 0 |
10/2008 | T2 Biosystems | Series B | 0 |
1/2004 | EngeneOS | Venture Round | - |
12/2011 | Permeon Biologics | Venture Round | 2.5M |
3/2005 | Tira Wireless | Series B | 2.5M |
4/2013 | Syros Pharmaceuticals | Series A | 30M |
1/2004 | TransMedics | Series B | 27.6M |
3/2017 | Boragen | Series A | 10M |
3/2012 | Receptos | Venture Round | 30M |
6/2017 | Rubius Therapeutics | Series B | 120M |
3/2018 | Rubius Therapeutics | Series C | 100M |
4/2008 | VisEn Medical | Series B | 0 |
10/2020 | Senda Biosciences | Series A | 88M |
10/2000 | Hypnion | Series A | 10.4M |
3/2005 | Tira Wireless | Debt Financing | 2.5M |
8/2009 | Novomer | Series B | 14M |
8/2008 | Quanterix | Series A | 15M |
5/2008 | Jinko Solar | Series A | - |
10/2011 | BlackDuck | Series E | 12M |
5/2004 | Ensemble Discovery | Series A | 15M |
11/2007 | Ensemble Discovery | Series B | 15M |
11/2021 | Generate Biomedicines | Series B | 0 |
5/2008 | Selecta Biosciences | Seed Round | 2.5M |
11/2007 | Novomer | Series A | 6.6M |
3/2006 | TransMedics | Series C | 0 |
4/2007 | Netuitive | Series D | 8M |
10/2017 | Visterra | Series C | 0 |
11/2017 | Codiak Biosciences | Series C | 76.5M |
7/2017 | Evelo Biosciences | Series B | 50M |
4/2010 | Selecta Biosciences | Series C | 15M |
12/2012 | Moderna Therapeutics | Venture Round | 40M |
7/2022 | Apriori Bio | Series A | 0 |
5/2022 | ProFound Therapeutics | Series A | 0 |
4/2022 | Tessera Therapeutics | Series C | 0 |
3/2022 | Vesalius Therapeutics | Series A | 0 |
11/2021 | Generate Biomedicines | Series B | 0 |
11/2021 | Alltrna | Venture Round | 0 |
10/2021 | CIBO Technologies | Series C | 0 |
9/2021 | YourBio Health | Venture Round | 0 |
8/2021 | Laronde | Series B | 0 |
7/2021 | Ring Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|